# Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

> **NCT00604721** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- Adult Primary Hepatocellular Carcinoma
- Advanced Adult Primary Liver Cancer
- Localized Unresectable Adult Primary Liver Cancer
- Recurrent Adult Primary Liver Cancer

## Interventions

- **DRUG:** selumetinib
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00604721
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2014-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00604721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00604721, "Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00604721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*